Ferring Advances Three Studies in ADSTILADRIN® (nadofaragene firadenovec-vncg) Clinical Trial Program
Ferring activates first sites in a three-arm study of ADSTILADRIN as a monotherapy or in combination with chemotherapy or an ...
pharmaphorum5d
FDA approves Adstiladrin as first gene therapy for NMIBC
Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...